USRE48286E1 - Steroids as agonists for FXR - Google Patents

Steroids as agonists for FXR Download PDF

Info

Publication number
USRE48286E1
USRE48286E1 US16/448,503 US200216448503A USRE48286E US RE48286 E1 USRE48286 E1 US RE48286E1 US 200216448503 A US200216448503 A US 200216448503A US RE48286 E USRE48286 E US RE48286E
Authority
US
United States
Prior art keywords
compound
formula
ethyl
fxr
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/448,503
Other languages
English (en)
Inventor
Roberto Pellicciari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23050302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE48286(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US16/448,503 priority Critical patent/USRE48286E1/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Assigned to INTERCEPT PHARMACEUTICALS, INC. reassignment INTERCEPT PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PELLICCIARI, ROBERTO
Assigned to INTERCEPT PHARMACEUTICALS reassignment INTERCEPT PHARMACEUTICALS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PELLICCIARI, ROBERTO
Publication of USRE48286E1 publication Critical patent/USRE48286E1/en
Application granted granted Critical
Assigned to U.S. BANK NATIONAL ASSOCIATION reassignment U.S. BANK NATIONAL ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INTERCEPT PHARMACEUTICALS, INC.
Assigned to INTERCEPT PHARMACEUTICALS, INC. reassignment INTERCEPT PHARMACEUTICALS, INC. CHANGE OF ADDRESS Assignors: INTERCEPT PHARMACEUTICALS, INC.
Assigned to INTERCEPT PHARMACEUTICALS, INC. reassignment INTERCEPT PHARMACEUTICALS, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 16488503 PREVIOUSLY RECORDED AT REEL: 060814 FRAME: 0702. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF ADDRESS. Assignors: INTERCEPT PHARMACEUTICALS, INC.
Assigned to INTERCEPT PHARMACEUTICALS, INC. reassignment INTERCEPT PHARMACEUTICALS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • Y10S514/893—

Definitions

  • the present invention relates to Farnesoid X receptors (FXR). More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same.
  • FXR Farnesoid X receptors
  • Farnesoid X Receptor is an orphan nuclear receptor initially identified from a rat liver cDNA library (BM. Forman, et al., Cell 81:687-693 (1995)) that is most closely related to the insect ecdysone receptor.
  • FXR is a member of the nuclear receptor family of ligand-activated transcription factors that includes receptors for the steroid, retinoid, and thyroid hormones (DJ. Mangelsdorf, et al., Cell 83:841-850 (1995)).
  • Northern and in situ analysis show that FXR is most abundantly expressed in the liver, intestine, kidney, and adrenal (BM.
  • FXR binds to DNA as a heterodimer with the 9-cis retinoic acid receptor (RXR).
  • RXR 9-cis retinoic acid receptor
  • the FXR/RXR heterodimer preferentially binds to response elements composed of two nuclear receptor half sites of the consensus AG(G/T)TCA organized as an inverted repeat and separated by a single nucleotide (IR-1 motif) (BM. Forman, et al., Cell 81:687-693 (1995)).
  • the bile acids that serve as FXR ligands include chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), and the taurine and glycine conjugates of these bile acids.
  • Bile acids are cholesterol metabolites that are formed in the liver and secreted into the duodenum of the intestine, where they have important roles in the solubilization and absorption of dietary lipids and vitamins. Most bile acids ( ⁇ 95%) are subsequently reabsorbed in the ileum and returned to the liver via the enterohepatic circulatory system. The conversion of cholesterol to bile acids in the liver is under feedback regulation: Bile acids down-regulate the transcription of cytochrome P450 7a (CYP7a), which encodes the enzyme that catalyzes the rate limiting step in bile acid biosynthesis.
  • CYP7a cytochrome P450 7a
  • the present invention provides compounds of formula I:
  • R is ethyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
  • the compound of formula (I) is in the form of the glycine or taurine conjugate.
  • the present invention provides 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholan-24-oic acid and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
  • the present invention provides 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -allyl-5 ⁇ -cholan-24-oic acid and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
  • the present invention provides compounds which are FXR agonists.
  • the present invention provides a pharmaceutical formulation comprising a compound of formula (I) and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a method for the prevention or treatment of an FXR mediated disease or condition.
  • the method comprises administering a therapeutically effective amount of a compound of formula (I).
  • the present invention also provides the use of a compound of formula (I) for the preparation of a medicament for the prevention or treatment of an FXR mediated disease or condition.
  • the present invention provides a method for the prevention or treatment of cardiovascular disease.
  • the method comprises administering a therapeutically effective amount of a compound of formula (I).
  • the present invention also provides the use of a compound according to claim 1 for the preparation of a medicament for the prevention or treatment of cardiovascular disease.
  • the cardiovascular disease is atherosclerosis.
  • the present invention provides a method for increasing HDL cholesterol.
  • the method comprises administering a therapeutically effective amount of a compound of formula (I).
  • the present invention also provides the use of a compound according to claim 1 for the preparation of a medicament for increasing HDL-cholesterol.
  • the present invention provides a method for lowering triglycerides.
  • the method comprises administering a therapeutically, effective amount of a compound of formula (I).
  • The-present invention also provides the use of a compound according to claim 1 for the preparation of a medicament for lowering triglycerides.
  • the present invention provides a method for the prevention or treatment of cholestatic liver disease.
  • the method comprises administering a therapeutically effective amount of a compound of formula (I).
  • the present invention also provides the use of a compound according to claim 1 for the preparation of a medicament for the prevention or treatment of cholestatic liver diseases.
  • the present invention provides a radiolabeled compound of formula (I).
  • the compound of formula (I) is tritiated.
  • the present invention provides a process for preparing a compound of formula (I) and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
  • the process comprises the steps of:
  • R is ethyl
  • the present invention provides compounds of formula I:
  • R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
  • Suitable pharmaceutically acceptable salts according to the present invention will be readily determined by one skilled in the art and will include, for example, basic salts such as metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium, and zinc or organic salts made from N,N′-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylendiamine, meglumine (N-methylglucamine), and procaine.
  • Such salts of the compounds of formula (I) may be prepared using conventional techniques, from the compound of Formula (I) by reacting, for example, the appropriate base with the compound of Formula (I).
  • salts of a compound of formula (I) should be pharmaceutically acceptable, but pharmaceutically unacceptable salts may conveniently be used to prepare the corresponding free base or pharmaceutically acceptable salts thereof.
  • solvate is a crystal form containing the compound of formula (I) or a pharmaceutically acceptable salt thereof and either a stoichiometric or a non-stoichiometric amount of a solvent.
  • Solvents include water, methanol, ethanol, or acetic acid.
  • reference to a compound of formula (I) is to any physical form of that compound, unless a particular form, salt or solvate thereof is specified.
  • amino acid conjugates refers to conjugates of the compounds of formula (I) with any suitable amino acid.
  • suitable amino acid conjugates of the compounds of formula (I) will have the added advantage of enhanced integrity in bile or intestinal fluids.
  • suitable amino acids include but are not limited to glycine and taurine.
  • the present invention encompasses the glycine and taurine conjugates of any of the compounds of formula (I).
  • Preferred compounds of formula (I) include compounds selected from the group consisting of 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholan-24-oic acid and their pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
  • the compounds of formula (I) are FXR agonists.
  • the term “agonist” refers to compounds which achieve at least 50% activation of FXR relative to CDCA, the appropriate positive control in the assay methods described in PCT Publication No. WO 00/37077 published 29 Jun. 2000 to Glaxo Group Limited, the subject matter of which is incorporated herein by reference in its entirety. More preferably, the compounds of this invention achieve 100% activation of FXR in the scintillation proximity assay or the HTRF assay as described in PCT Publication No. WO 00/37077.
  • the compounds of the formula (I) are useful for a variety of medicinal purposes.
  • the compounds of formula (I) may be used in methods for the prevention or treatment of FXR mediated diseases and conditions.
  • FXR mediated diseases or conditions include cardiovascular diseases including atherosclerosis, arteriosclerosis, hypercholesteremia, and hyperlipidemia.
  • cardiovascular diseases including atherosclerosis, arteriosclerosis, hypercholesteremia, and hyperlipidemia.
  • the compounds of formula (I) are useful in the treatment and prevention of cardiovascular disease including atherosclerosis and hypercholesteremia.
  • the compounds of formula (I) are also useful for increasing HDL-cholesterol, and lowering triglycerides.
  • the compounds of the present invention are useful for the prevention and treatment of cholestatic liver diseases.
  • the compounds of the present invention increase the flow of bile acid. Increased flow of bile acids improves the flux of bile acids from the liver to the intestine. See, C. Sinal, Cell 102: 731-744 (9000).
  • FXR null mice demonstrate that FXR plays a central role in bile acid homeostasis, and is therefore critical to lipid homeostasis by virtue of the regulation of enzymes and transporters that are critical to lipid catabolism and excretion. FXR therefore is an important target for the treatment of a number of cholestatic liver disease and other lipid related diseases and conditions.
  • the methods of the present invention are useful for the treatment of mammals generally and particularly humans.
  • the methods of the present invention comprise the step of administering a therapeutically effective amount of the compound of formula (I).
  • therapeutically effective amount refers to an amount of the compound of formula (I) which is sufficient to achieve the stated effect. Accordingly, a therapeutically effective amount of a compound of formula (I) used in the method for the prevention or treatment of FXR mediated diseases or conditions will be an amount sufficient to prevent or treat the FXR mediated disease or condition. Similarly, a therapeutically effective amount of a compound of formula (I) for use in the method for the prophylaxis or treatment of cholestatic liver diseases or increasing bile flow will be an amount sufficient to increase bile flow to the intestine.
  • a typical daily dose for the treatment of FXR mediated diseases and conditions may be expected to lie in the range of from about 0.01 mg/kg to about 100 mg/kg. This dose may be administered as a single unit dose or as several separate unit doses or as a continuous infusion. Similar dosages would be applicable for the treatment of other diseases, conditions and therapies including the prophylaxis and treatment of cholestatic liver diseases.
  • compositions comprising, as active ingredient, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutical carrier or diluent.
  • These pharmaceutical compositions may be used in the prophylaxis and treatment of the foregoing diseases or conditions and in cardiovascular therapies as mentioned above.
  • the carrier must be pharmaceutically acceptable and must be compatible with, i.e. not have a deleterious effect upon, the other ingredients in the composition.
  • the carrier may be a solid or liquid and is preferably formulated as a unit dose formulation, for example, a tablet which may contain from 0.05 to 95% by weight of the active ingredient. If desired other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
  • Possible formulations include those suitable for oral, sublingual, buccal, parenteral (for example subcutaneous, intramuscular, or intravenous), rectal, topical including transdermal, intranasal and inhalation administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound, but where possible, oral administration is preferred for the prevention and treatment of FXR mediated diseases and conditions.
  • Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets, lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.
  • Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the active compound in an inert base, such as gelatine and glycerine or sucrose acacia.
  • a flavoured base such as sugar and acacia or tragacanth
  • pastilles comprising the active compound in an inert base, such as gelatine and glycerine or sucrose acacia.
  • Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended recipient. Additional formulations suitable for parenteral administration include formulations containing physiologically suitable co-solvents and/or complexing agents such as surfactants and cyclodextrins. Oil-in-water emulsions are also suitable formulations for parenteral formulations. Although such solutions are preferably administered intravenously, they may also be administered by subcutaneous or intramuscular injection.
  • Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient in one or more solid carriers forming the suppository base, for example, cocoa butter.
  • Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils.
  • Suitable carriers for such formulations include petroleum jelly, lanolin, polyethyleneglycols, alcohols, and combinations thereof.
  • Formulations of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compound with liquids or finely divided solid carriers or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
  • a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
  • one or more optional ingredients such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
  • Suitable formulations for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers, or insufflators.
  • the particle size of the powder or droplets is typically in the range 0.5-10 ⁇ m, preferably 1-5 ⁇ m, to ensure delivery into the bronchial tree.
  • a particle size in the range 10-500 ⁇ m is preferred to ensure retention in the nasal cavity.
  • Metered dose inhalers are pressurised aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquefied propellant. During use, these devices discharge the formulation through a valve adapted to deliver a metered volume, typically from 10 to 150 ⁇ l, to produce a fine particle spray containing the active ingredient.
  • Suitable propellants include certain chlorofluorocarbon compounds, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof.
  • the formulation may additionally contain one or more co-solvents, for example, ethanol surfactants, such as oleic acid or sorbitan trioleate, anti-oxidants and suitable flavouring agents.
  • Nebulisers are commercially available devices that transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas typically air or oxygen, through a narrow venturi orifice, or by means of ultrasonic agitation.
  • Suitable formulations for use in nebulisers consist of the active ingredient in a liquid carrier and comprising up to 40% w/w of the formulation, preferably less than 20% w/w.
  • the carrier is typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, for example, sodium chloride.
  • Optional additives include preservatives if the formulation is not prepared sterile, for example, methyl hydroxy-benzoate, anti-oxidants, flavouring agents, volatile oils, buffering agents and surfactants.
  • Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or taken into the nasal cavity in the manner of a snuff.
  • the powder is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened in situ and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump.
  • the powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant.
  • the active ingredient typically comprises from 0.1 to 100 w/w of the formulation.
  • formulations of the present invention may include other agents known to those skilled in the art of pharmacy, having regard for the type of formulation in issue.
  • formulations suitable for oral administration may include flavouring agents and formulations suitable for intranasal administration may include perfumes.
  • R is ethyl
  • the compounds of the present invention can be prepared by the process comprising a) reacting 3 ⁇ -hydroxy-7-keto-5 ⁇ -cholan-24-oic acid with 3,4-dihydropyrane to prepare 3 ⁇ -tetrahydropyranyloxy-7-keto-5 ⁇ -cholan-24-oic acid; b) reacting 3 ⁇ -tetrahydropyranyloxy-7-keto-5 ⁇ -cholan-24-oic acid with an alkyl bromide of the formula R—Br where R is ethyl to prepare a compound of formula (II); c) reacting the compound of formula (II) with sodium borohydride to prepare a compound of formula (III); d) reacting the compound of formula (III) with sodium hydroxide to prepare the compound of formula (I).
  • the compounds of formula (I) are conveniently prepared by reacting the compounds of formula (III) with sodium hydroxide in a suitable solvent at ambient temperature.
  • suitable solvents include lower alcohols, such as ethanol.
  • the reaction mixture may optionally be acidified with an appropriate acid such as hydrochloric acid.
  • the compounds of formula (III) are conveniently prepared by reacting compounds of formula (II) with sodium borohydride in a suitable solvent at ambient temperature.
  • suitable solvents include lower alcohols such as ethanol.
  • the compounds of formula (II) are conveniently prepared by reacting 3 ⁇ -tetrahydropyranyloxy-7-keto-5 ⁇ -cholan-24-oic acid with an alkyl bromide of the formula R—Br where R is ethyl in a suitable solvent and in the presence of n-Butyl lithium and HMPA in diisopropylamine.
  • Polar solvents such as tetrahydrofuran are useful for conducting the reaction.
  • the reaction is carried out at cold temperatures such as about ⁇ 70 to ⁇ 80° C.
  • 3 ⁇ -Tetrahydropyranyloxy-7-keto-5 ⁇ -cholan-24-oic acid can conveniently be prepared from 3 ⁇ -hydroxy-7-keto-5 ⁇ -cholan-24-oic acid by reacting with 3,4-dihydropyrane in p-toluenesulfonic acid.
  • Radiolabeled compounds of formula (I) can be prepared using conventional techniques.
  • radiolabeled compounds of formula (I) can be prepared by reacting the compound of formula (I) with tritium gas in the presence of an appropriate catalyst to produce radiolabeled compounds of formula (I).
  • the compounds of formula (I) are tritiated.
  • radiolabeled compounds of formula (I) are useful in assays for the lo identification of compounds which interact with FXR such as those described in PCT Publication No. WO 00/37077 already incorporated herein.
  • n-Butyl lithium (21.1 ml, 1.6M solution in hexane) and HMPA (4.3 ml) were added dropwise at ⁇ 78° C. to a solution of diisopropylamine (4.1 ml, 33.7 mmol) in 250 ml of dry THF.
  • the system was held at ⁇ 78° C. for an additional 30 min and then, 3 ⁇ -tetrahydropyranyloxy-7-keto-5 ⁇ -cholan-24-oic acid (2) (5 g, 10.5 mmol) dissolved in 50 ml of dry THF was cooled to ⁇ 78° C. and added dropwise to the mixture.
  • Ethyl 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholan-24-oate (4) (0.10 g, 0.22 mmol) was dissolved in 15 ml of 96% EtOH and added to 10% NaOH in 96% EtOH (2 ml, 5 mmol). The mixture was refluxed for 4 hours. The mixture was acidified with 3N HCl and extracted with ethyl acetate (3 ⁇ 20 ml). The combined organic fractions were washed with a saturated NaCl solution (1'50 ml), dried with Na 2 SO 4 and evaporated under vacuum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • External Artificial Organs (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
US16/448,503 2001-03-12 2002-02-21 Steroids as agonists for FXR Active 2027-11-16 USRE48286E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/448,503 USRE48286E1 (en) 2001-03-12 2002-02-21 Steroids as agonists for FXR

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27495901P 2001-03-12 2001-03-12
PCT/EP2002/001832 WO2002072598A1 (en) 2001-03-12 2002-02-21 Steroids as agonists for fxr
US16/448,503 USRE48286E1 (en) 2001-03-12 2002-02-21 Steroids as agonists for FXR
US10/471,549 US7138390B2 (en) 2001-03-12 2002-02-21 Steroids as agonists for FXR

Publications (1)

Publication Number Publication Date
USRE48286E1 true USRE48286E1 (en) 2020-10-27

Family

ID=23050302

Family Applications (9)

Application Number Title Priority Date Filing Date
US16/448,503 Active 2027-11-16 USRE48286E1 (en) 2001-03-12 2002-02-21 Steroids as agonists for FXR
US10/471,549 Ceased US7138390B2 (en) 2001-03-12 2002-02-21 Steroids as agonists for FXR
US11/602,307 Expired - Lifetime US7786102B2 (en) 2001-03-12 2006-11-21 Steroids as agonists for FXR
US12/547,147 Expired - Fee Related US8058267B2 (en) 2001-03-12 2009-08-25 Steroids as agonists for FXR
US13/288,558 Expired - Fee Related US8377916B2 (en) 2001-03-12 2011-11-03 Steroids as agonists for FXR
US13/761,889 Expired - Fee Related US8969330B2 (en) 2001-03-12 2013-02-07 Steroids as agonists for FXR
US14/632,139 Abandoned US20150166598A1 (en) 2001-03-12 2015-02-26 Steroids as Agonists for FXR
US15/016,802 Expired - Lifetime US9732117B2 (en) 2001-03-12 2016-02-05 Steroids as agonists for FXR
US15/645,136 Expired - Fee Related US10421772B2 (en) 2001-03-12 2017-07-10 Steroids as agonists for FXR

Family Applications After (8)

Application Number Title Priority Date Filing Date
US10/471,549 Ceased US7138390B2 (en) 2001-03-12 2002-02-21 Steroids as agonists for FXR
US11/602,307 Expired - Lifetime US7786102B2 (en) 2001-03-12 2006-11-21 Steroids as agonists for FXR
US12/547,147 Expired - Fee Related US8058267B2 (en) 2001-03-12 2009-08-25 Steroids as agonists for FXR
US13/288,558 Expired - Fee Related US8377916B2 (en) 2001-03-12 2011-11-03 Steroids as agonists for FXR
US13/761,889 Expired - Fee Related US8969330B2 (en) 2001-03-12 2013-02-07 Steroids as agonists for FXR
US14/632,139 Abandoned US20150166598A1 (en) 2001-03-12 2015-02-26 Steroids as Agonists for FXR
US15/016,802 Expired - Lifetime US9732117B2 (en) 2001-03-12 2016-02-05 Steroids as agonists for FXR
US15/645,136 Expired - Fee Related US10421772B2 (en) 2001-03-12 2017-07-10 Steroids as agonists for FXR

Country Status (16)

Country Link
US (9) USRE48286E1 (enrdf_load_stackoverflow)
EP (1) EP1392714B1 (enrdf_load_stackoverflow)
JP (2) JP4021327B2 (enrdf_load_stackoverflow)
AT (1) ATE303399T1 (enrdf_load_stackoverflow)
AU (1) AU2002308295B2 (enrdf_load_stackoverflow)
BE (1) BE2017C018I2 (enrdf_load_stackoverflow)
CA (1) CA2440680C (enrdf_load_stackoverflow)
CY (1) CY2017020I2 (enrdf_load_stackoverflow)
DE (1) DE60205891T2 (enrdf_load_stackoverflow)
DK (1) DK1392714T3 (enrdf_load_stackoverflow)
ES (1) ES2248581T3 (enrdf_load_stackoverflow)
FR (1) FR17C0003I2 (enrdf_load_stackoverflow)
IL (2) IL157816A0 (enrdf_load_stackoverflow)
NL (1) NL300877I2 (enrdf_load_stackoverflow)
NO (2) NO326134B1 (enrdf_load_stackoverflow)
WO (1) WO2002072598A1 (enrdf_load_stackoverflow)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48286E1 (en) 2001-03-12 2020-10-27 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) * 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
PT1734970E (pt) 2004-03-12 2015-03-11 Intercept Pharmaceuticals Inc Tratamento de fibrose utilizando ligandos de rfx
JPWO2005092328A1 (ja) * 2004-03-29 2008-02-07 財団法人ヒューマンサイエンス振興財団 Ｆｘｒ活性化化合物
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US7618956B2 (en) 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
JP5222846B2 (ja) * 2006-06-27 2013-06-26 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介疾患または状態の予防または治療のためのｆｘｒリガンドとしての胆汁酸誘導体
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
KR100846441B1 (ko) * 2006-12-22 2008-07-16 재단법인서울대학교산학협력재단 스테롤 계 유도체를 함유하는 약제학적 조성물, 건강식품조성물, 화장품 조성물 및 파나소이드 엑스 핵 수용체 활성억제제 조성물
CN101679476B (zh) 2007-01-19 2014-05-07 英特塞普特医药品公司 23取代的胆汁酸作为tgr5调节剂及其使用方法
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
SG10201400162QA (en) 2008-11-19 2014-05-29 Intercept Pharmaceuticals Inc Tgr5 modulators and methods of use thereof
WO2010069604A1 (en) 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
SG10201607230SA (en) * 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
JP6272888B2 (ja) 2012-10-26 2018-01-31 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体を調製するためのプロセス
MX2015006710A (es) * 2012-11-28 2016-01-15 Intercept Pharmaceuticals Inc Tratamiento de las enfermedades pulmonares.
US20160151486A1 (en) 2013-06-13 2016-06-02 Fast Foward Pharmaceuticals B.V. CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis
EP3043865B1 (en) 2013-09-11 2020-11-04 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
WO2015075557A2 (en) 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
CN104876995B (zh) * 2014-02-27 2016-09-07 人福医药集团股份公司 鹅去氧胆酸衍生物的制备方法
SI3626725T1 (sl) * 2014-05-29 2023-04-28 Bar Pharmaceuticals S.R.L. Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
EP3006557A1 (en) 2014-10-07 2016-04-13 Heinrich-Heine-Universität Düsseldorf Bile acids for inducing hepatic differentiation
CN105585603B (zh) * 2014-10-21 2019-05-24 重庆医药工业研究院有限责任公司 一种制备奥贝胆酸中间体的方法
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CN111944006B (zh) * 2014-11-17 2021-12-17 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
TWI686401B (zh) * 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（三）
MX375864B (es) 2014-11-19 2025-03-07 Nzp Uk Ltd Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
CA2968309A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
WO2016127019A2 (en) 2015-02-06 2016-08-11 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
BR112017017238A2 (pt) 2015-02-11 2018-04-10 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
EP3277286B1 (en) 2015-03-31 2021-04-21 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
TN2017000426A1 (en) 2015-04-07 2019-04-12 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106290594B (zh) * 2015-05-27 2020-07-17 中美华世通生物医药科技（武汉）有限公司 测定奥贝胆酸片溶出含量的方法
CZ2015504A3 (cs) 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
CN106478759A (zh) * 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CA2998876A1 (en) 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
CA2999302A1 (en) 2015-09-24 2017-03-30 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
AU2016350690C1 (en) * 2015-11-06 2020-04-23 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN106854229A (zh) * 2015-12-08 2017-06-16 陈剑 一类脂肪酸盐,其制备及其在医药上的应用
WO2017115324A1 (en) 2016-01-01 2017-07-06 Lupin Limited Solid forms of obeticholic acid and processes thereof
CN109071593B (zh) 2016-01-28 2021-01-15 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂
ES2909907T3 (es) * 2016-02-10 2022-05-10 Dr Reddys Laboratories Ltd Proceso de purificación que implica la sal de amina del ácido obeticólico
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
CN109467585A (zh) * 2016-03-11 2019-03-15 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
CN105541953B (zh) * 2016-03-15 2017-11-21 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法
CN107188917A (zh) * 2016-03-15 2017-09-22 正大天晴药业集团股份有限公司 奥贝胆酸盐及其药物组合物
US11419878B2 (en) 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
WO2017170858A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
CN109195607A (zh) * 2016-03-31 2019-01-11 英特塞普特医药品公司 具有活性成分的高化学稳定性的薄膜包衣片剂
EP3440092A1 (en) 2016-04-04 2019-02-13 Dipharma Francis S.r.l. Method for preparing a farnesoid x receptor agonist
ITUA20162272A1 (it) * 2016-04-04 2017-10-04 Dipharma Francis Srl Procedimento per la preparazione di un agonista del recettore farnesoide x
EP3228306A1 (en) 2016-04-04 2017-10-11 ratiopharm GmbH Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
CN109071452A (zh) 2016-04-13 2018-12-21 英特塞普特医药品公司 治疗癌症的方法
TW201738254A (zh) 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
EA038580B9 (ru) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Агонист fxr, представляющий собой производное стероидов
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
WO2017208165A1 (en) 2016-06-01 2017-12-07 Dr. Reddy’S Laboratories Limited Process for preparation of obeticholic acid
CZ2016385A3 (cs) 2016-06-28 2018-01-10 Zentiva, K.S. Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
TWI606565B (zh) * 2016-08-31 2017-11-21 金寶電子工業股份有限公司 封裝結構及其製作方法
EP3293196A1 (en) 2016-09-09 2018-03-14 Hexal AG Process for purifying obeticholic acid
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
EP3305799A3 (en) 2016-10-07 2018-06-20 Lupin Limited Salts of obeticholic acid
JP7057783B2 (ja) 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニル尿素胆汁酸誘導体の調製方法
CN108264532B (zh) * 2016-12-30 2021-02-26 上海现代制药股份有限公司 一种奥贝胆酸的制备方法及其中间体
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
WO2018153933A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar agonist with a fxr agonist
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
BR112019020780A2 (pt) 2017-04-07 2020-04-28 Enanta Pharm Inc processo para preparação de derivados de ácido biliar de carbamato de sulfonila
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
CN109134572A (zh) * 2017-06-19 2019-01-04 中国科学院上海药物研究所 胆酸衍生物及其制备方法和用途
US11189472B2 (en) * 2017-07-17 2021-11-30 Applied Materials, Inc. Cathode assembly having a dual position magnetron and centrally fed coolant
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
US10611793B1 (en) 2017-11-27 2020-04-07 Teva Czech Industries S.R.O. Solid state forms of obeticholic acid salts
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
US10689391B2 (en) * 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
ES2779985B2 (es) 2019-02-20 2021-03-04 Moehs Iberica Sl Sal de dietilamina del ácido 3alfa-tetrahidropiraniloxi-6alfa-etil-7alfa-hidroxi-5ß-colánico
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US20210261599A1 (en) 2018-08-24 2021-08-26 Solara Active Pharma Sciences Limited Process for the Preparation of Obeticholic Acid and Intermediates Used In the Process Thereof
CN111718388A (zh) 2019-03-19 2020-09-29 苏州泽璟生物制药股份有限公司 鹅去氧胆酸衍生物的制备方法
CN110025591A (zh) * 2019-04-29 2019-07-19 郑州泰丰制药有限公司 一种奥贝胆酸自乳化制剂及其软胶囊
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2020243590A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
JP2023510274A (ja) 2020-01-15 2023-03-13 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用
CN112341516B (zh) * 2020-11-14 2022-07-15 湖南科瑞生物制药股份有限公司 5,6-环氧类固醇类化合物及其制备方法和应用
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2024104960A1 (en) 2022-11-15 2024-05-23 Synthon B.V. Stable formulation comprising obeticholic acid

Citations (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2615902A (en) 1950-10-24 1952-10-28 Merck & Co Inc Chemical compounds and processes for preparing the same
US3859437A (en) 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US4072695A (en) 1972-09-21 1978-02-07 Intellectual Property Development Corporation 3α,7α-Dihydroxy-cholanic acid derivatives
US4282161A (en) 1979-05-23 1981-08-04 Armand Guillemette Novel purification process
US4316848A (en) 1979-07-12 1982-02-23 Blasinachim S.P.A Process for the purification of ursodeoxycholic acid
US4379093A (en) 1981-04-14 1983-04-05 Erregierre S.P.A. Process for preparing high purity ursodeoxycholic acid
US4425274A (en) 1978-12-15 1984-01-10 Roussel Uclaf Process for the production of ursodesoxycholic acid
EP0101554A2 (en) 1982-07-29 1984-02-29 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
EP0124068A1 (en) 1983-04-29 1984-11-07 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
EP0135782A2 (en) 1983-08-18 1985-04-03 GIULIANI S.p.A. New derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
EP0186023A2 (en) 1984-12-21 1986-07-02 Lehner A.G. Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
US4721709A (en) 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
EP0312867A1 (en) 1987-10-20 1989-04-26 GIULIANI S.p.A. Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
US4895726A (en) 1988-02-26 1990-01-23 Fournier Innovation Et Synergie Novel dosage form of fenofibrate
EP0393493A2 (en) 1989-04-17 1990-10-24 GIULIANI S.p.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5128481A (en) * 1989-12-13 1992-07-07 Mitsubishi Kasei Corporation Pyrazolyl derivatives
JPH04250093A (ja) 1991-01-18 1992-09-04 Kanzaki Paper Mfg Co Ltd 感熱記録体
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1997031907A1 (en) 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1997036579A1 (en) 1996-03-30 1997-10-09 Glaxo Group Limited Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity
WO1998002159A1 (en) 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
US6060465A (en) 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
WO2000028332A1 (en) 1998-11-09 2000-05-18 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
WO2000037077A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
WO2000057915A1 (en) 1999-03-26 2000-10-05 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
WO2000076523A1 (en) 1999-06-11 2000-12-21 Allergan Sales, Inc. Methods for modulating fxr receptor activity
US6200998B1 (en) 1997-12-19 2001-03-13 Merck & Co., Inc. Arylthiazolidinedione derivitives
WO2001030343A1 (en) 1999-10-22 2001-05-03 Merck & Co., Inc. Pharmaceuticals for treating obesity
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US20020094977A1 (en) 2000-06-15 2002-07-18 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
WO2002064125A2 (en) 2001-02-13 2002-08-22 Sumitomo Pharmaceuticals Company, Limited Use of a farnesoid x receptor antagonist for treating hyperlipidemia
WO2002072598A1 (en) 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
WO2003016288A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Fxr nr1h4 nuclear receptor binding compounds
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
WO2003015777A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
US20030077329A1 (en) 2001-10-19 2003-04-24 Kipp James E Composition of and method for preparing stable particles in a frozen aqueous matrix
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
WO2003043581A2 (en) 2001-11-19 2003-05-30 Allergan, Inc. Composition and method for modulating bar/fxr receptor activity
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
WO2003090745A1 (en) 2002-04-25 2003-11-06 Smithkline Beecham Corporation Fxr agonists for hepatoprotection and treatment of cholestasis
EP1378749A1 (en) 2001-04-12 2004-01-07 Takeda Chemical Industries, Ltd. Screening method
WO2004007521A2 (en) 2002-07-12 2004-01-22 Roberto Pellicciari Bile acid derivatives as agonists of the farnesoid x receptor
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
EP1473042A1 (en) 1999-03-26 2004-11-03 City of Hope Controlling cholesterol catabolism via FXR receptor and screening for FXR receptor modulators
WO2005032549A1 (en) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
US6993380B1 (en) 2003-06-04 2006-01-31 Cleveland Medical Devices, Inc. Quantitative sleep analysis method and system
WO2006044391A1 (en) 2004-10-14 2006-04-27 Intercept Pharmaceuticals Inc. A method of reducing drug-induced adverse side effects in a patient
WO2006122977A2 (en) 2005-05-19 2006-11-23 Erregierre S.P.A. PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID
US7157101B2 (en) 1998-12-09 2007-01-02 G.D. Searle, Llc Micronized eplerenone compositions
US20070087961A1 (en) 2004-03-11 2007-04-19 Wolfram Eichner Conjugates of hydroxyalkyl starch and erythropoietin
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2008062475A2 (en) 2006-10-26 2008-05-29 Cadila Healthcare Limited Pharmaceutical compositions of ursodiol
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
US20090062526A1 (en) 2007-08-28 2009-03-05 Yu Donna D novel method of synthesizing alkylated bile acid derivatives
WO2010059853A1 (en) 2008-11-19 2010-05-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and method of use thereof
US7858608B2 (en) 2006-02-14 2010-12-28 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
WO2012072689A1 (en) 2010-11-30 2012-06-07 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013057741A2 (en) 2011-10-21 2013-04-25 Genovo Development Services Limited Pharmaceutical compositions of ursodeoxycholic acid
US20130345188A1 (en) 2012-06-19 2013-12-26 Intercept Pharmaceuticals, Inc. Preparation and Uses of Obeticholic Acid
US20140371190A1 (en) 2013-05-14 2014-12-18 TES Pharma SrI. Farnesoid X receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3003607C2 (de) 1980-02-01 1984-01-05 Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel Schaltungsanordnung zur partiellen Nachkorrektur von Farberkennungsräumen bei der Farberkennung
US4982868A (en) * 1989-11-07 1991-01-08 Robbins Edward S Iii Bail type pitcher for thin walled container
US6639057B1 (en) * 1998-03-26 2003-10-28 Kyowa Hakko Kogyo Co., Ltd. Monoclonal antibody against human telomerase catalytic subunit

Patent Citations (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2615902A (en) 1950-10-24 1952-10-28 Merck & Co Inc Chemical compounds and processes for preparing the same
US3859437A (en) 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US4072695A (en) 1972-09-21 1978-02-07 Intellectual Property Development Corporation 3α,7α-Dihydroxy-cholanic acid derivatives
US4425274A (en) 1978-12-15 1984-01-10 Roussel Uclaf Process for the production of ursodesoxycholic acid
US4282161A (en) 1979-05-23 1981-08-04 Armand Guillemette Novel purification process
US4316848A (en) 1979-07-12 1982-02-23 Blasinachim S.P.A Process for the purification of ursodeoxycholic acid
US4379093A (en) 1981-04-14 1983-04-05 Erregierre S.P.A. Process for preparing high purity ursodeoxycholic acid
EP0101554A2 (en) 1982-07-29 1984-02-29 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
EP0124068A1 (en) 1983-04-29 1984-11-07 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
EP0135782A2 (en) 1983-08-18 1985-04-03 GIULIANI S.p.A. New derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
US4721709A (en) 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
EP0186023A2 (en) 1984-12-21 1986-07-02 Lehner A.G. Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
EP0312867A1 (en) 1987-10-20 1989-04-26 GIULIANI S.p.A. Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them
US4921848A (en) 1987-10-20 1990-05-01 Gipharmex S.P.A. Biliary acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US4895726A (en) 1988-02-26 1990-01-23 Fournier Innovation Et Synergie Novel dosage form of fenofibrate
EP0393493A2 (en) 1989-04-17 1990-10-24 GIULIANI S.p.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5061701A (en) 1989-04-17 1991-10-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5128481A (en) * 1989-12-13 1992-07-07 Mitsubishi Kasei Corporation Pyrazolyl derivatives
JPH04250093A (ja) 1991-01-18 1992-09-04 Kanzaki Paper Mfg Co Ltd 感熱記録体
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1997031907A1 (en) 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1997036579A1 (en) 1996-03-30 1997-10-09 Glaxo Group Limited Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity
WO1998002159A1 (en) 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance
US6060465A (en) 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
US6200998B1 (en) 1997-12-19 2001-03-13 Merck & Co., Inc. Arylthiazolidinedione derivitives
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
EP1137940A1 (en) 1998-10-23 2001-10-04 Glaxo Group Limited Assays for ligands for nuclear receptors
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
WO2000028332A1 (en) 1998-11-09 2000-05-18 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US7157101B2 (en) 1998-12-09 2007-01-02 G.D. Searle, Llc Micronized eplerenone compositions
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
WO2000037077A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
EP1140079A1 (en) 1998-12-23 2001-10-10 Glaxo Group Limited Assays for ligands for nuclear receptors
US6984650B2 (en) 1998-12-23 2006-01-10 Smithkline Beecham Corporation Use of FXR ligands
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
EP1165135A1 (en) 1999-03-26 2002-01-02 City of Hope Methods of screening for compounds modulating fxr receptors
WO2000057915A1 (en) 1999-03-26 2000-10-05 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
EP1473042A1 (en) 1999-03-26 2004-11-03 City of Hope Controlling cholesterol catabolism via FXR receptor and screening for FXR receptor modulators
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1185277A1 (en) 1999-06-11 2002-03-13 Allergan Sales, Inc. Methods for modulating fxr receptor activity
WO2000076523A1 (en) 1999-06-11 2000-12-21 Allergan Sales, Inc. Methods for modulating fxr receptor activity
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
WO2001030343A1 (en) 1999-10-22 2001-05-03 Merck & Co., Inc. Pharmaceuticals for treating obesity
US20020094977A1 (en) 2000-06-15 2002-07-18 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020120137A1 (en) 2000-09-05 2002-08-29 Tularik Inc. FXR modulators
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
WO2002064125A2 (en) 2001-02-13 2002-08-22 Sumitomo Pharmaceuticals Company, Limited Use of a farnesoid x receptor antagonist for treating hyperlipidemia
US8969330B2 (en) 2001-03-12 2015-03-03 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US7786102B2 (en) 2001-03-12 2010-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
US20150166598A1 (en) 2001-03-12 2015-06-18 Intercept Pharmaceuticals, Inc. Steroids as Agonists for FXR
US10421772B2 (en) 2001-03-12 2019-09-24 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
WO2002072598A1 (en) 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
US20140024631A1 (en) 2001-03-12 2014-01-23 Intercept Pharmaceuticals, Inc. Steroids as Agonists for FXR
US9732117B2 (en) 2001-03-12 2017-08-15 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US8377916B2 (en) 2001-03-12 2013-02-19 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US8058267B2 (en) 2001-03-12 2011-11-15 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
EP1378749A1 (en) 2001-04-12 2004-01-07 Takeda Chemical Industries, Ltd. Screening method
WO2003015771A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Fxr nr1h4 nuclear receptor binding compounds
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
WO2003016288A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Fxr nr1h4 nuclear receptor binding compounds
WO2003015777A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
US20030130296A1 (en) 2001-08-13 2003-07-10 Ulrike Bauer FXR NR1H4 nuclear receptor binding compounds
WO2003030612A2 (en) 2001-10-05 2003-04-17 City Of Hope Methods for modulating activity of the fxr nuclear receptor
EP1536812A2 (en) 2001-10-05 2005-06-08 City Of Hope Methods for modulating activity of the fxr nuclear receptor
US20030077329A1 (en) 2001-10-19 2003-04-24 Kipp James E Composition of and method for preparing stable particles in a frozen aqueous matrix
WO2003043581A2 (en) 2001-11-19 2003-05-30 Allergan, Inc. Composition and method for modulating bar/fxr receptor activity
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
WO2003090745A1 (en) 2002-04-25 2003-11-06 Smithkline Beecham Corporation Fxr agonists for hepatoprotection and treatment of cholestasis
WO2004007521A2 (en) 2002-07-12 2004-01-22 Roberto Pellicciari Bile acid derivatives as agonists of the farnesoid x receptor
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
US6993380B1 (en) 2003-06-04 2006-01-31 Cleveland Medical Devices, Inc. Quantitative sleep analysis method and system
WO2005032549A1 (en) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
WO2005082925A2 (en) 2004-02-26 2005-09-09 Intercept Pharmaceuticals Inc. Novel steroid agonist for fxr
US20070087961A1 (en) 2004-03-11 2007-04-19 Wolfram Eichner Conjugates of hydroxyalkyl starch and erythropoietin
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
US20060069070A1 (en) 2004-03-12 2006-03-30 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
WO2006044391A1 (en) 2004-10-14 2006-04-27 Intercept Pharmaceuticals Inc. A method of reducing drug-induced adverse side effects in a patient
WO2006122977A2 (en) 2005-05-19 2006-11-23 Erregierre S.P.A. PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID
US7994352B2 (en) 2005-05-19 2011-08-09 Intercept Pharmaceuticals, Inc. Process for preparing 3a(β)-7a(β)-dihydroxy-6a(β)-alkyl-5β-cholanic acid
US7858608B2 (en) 2006-02-14 2010-12-28 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
US20080182832A1 (en) 2006-06-27 2008-07-31 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2008062475A2 (en) 2006-10-26 2008-05-29 Cadila Healthcare Limited Pharmaceutical compositions of ursodiol
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090062526A1 (en) 2007-08-28 2009-03-05 Yu Donna D novel method of synthesizing alkylated bile acid derivatives
WO2010059853A1 (en) 2008-11-19 2010-05-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and method of use thereof
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
WO2012072689A1 (en) 2010-11-30 2012-06-07 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013057741A2 (en) 2011-10-21 2013-04-25 Genovo Development Services Limited Pharmaceutical compositions of ursodeoxycholic acid
US20130345188A1 (en) 2012-06-19 2013-12-26 Intercept Pharmaceuticals, Inc. Preparation and Uses of Obeticholic Acid
US20140371190A1 (en) 2013-05-14 2014-12-18 TES Pharma SrI. Farnesoid X receptor modulators

Non-Patent Citations (95)

* Cited by examiner, † Cited by third party
Title
Aldini et al. "Relationship between structure and intestinal absorption of bile acids with a steroid or side-chain modification," Steroids (1996) 61(10):590-597.
Aulton, ed. "The Design of Dosage Forms", Pharmaceutics—The Science of Dosage Form Design, 1988, Chapter 1, p. 1-13.
Badger, "Biological Activity of Compounds in Homologous Series", 1946, Nature, No. 4017, p. 585.
Bishop-Bailey et al. "Expression and activation of the farnesoid X receptor in the vasculature," Proc. Natl. Acad. Sci. U.S.A. (2004) 101(10):3668-3673.
Bousquet et al. "Determination of chenodeoxycholic acid in pharmaceutical preparations of ursodeoxycholic acid by high performance liquid chromatography with coulometric electrochemical detection", Journal of Liquid Chromatography & Related Technologies, 1997, vol. 20, No. 5, p. 757-770.
Byrn et al. "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, 1995, vol. 12, No. 7, p. 945-954.
Center et al., "Chronic liver disease: current concepts of disease mechanisms," J. Small Anim. Pract. (1999) 40(3): 106-114.
Chaumeil, "Micronization: A Method of Improving the Bioavailability of Poorly Soluble Drugs," Methods and Findings in Experimental and Clinical Pharmacology, 1998, vol. 20, No. 3, p. 211-215.
Chenodiol Label, Nexgen Pharma, Inc., Rev. Sep. 2019, 9 pages.
Choi et al. "Amorphous Ultrafine Particle Preparation For Improvement of Bioavailability of Insoluble Drugs: Grinding Characteristics of Fine Grinding Mills", International Journal of Mineral Processing, 2004, 74S, p. S165-S172.
Chu et al. "Effect of Particle Size on the Dissolution Behaviors of Poorly Water-soluble Drugs", Archives of Pharmacal Research, 2012, vol. 35, No. 7, p. 1187-1195.
Clerici et al., "Effect of Intraduodenal Administration of 23-Methyl-UDCA Diastereoisomers on Bile Flow in Hamsters," DiQ. Dis. Sci. (1992) 37(5):791-7.
Costantino et al., "Evaluation of Hydrophobic/hydrophilic Balance of Bile Acids by Comparative Molecular Field Analysis (CoMFA)," Steroids, 2000, vol. 65, p. 483-489.
Delalonde et al., "Impact of Physicochemical Environment on the Super Disintegrant Functionality of Cross-Linked Carboxymethyl Sodium Starch: Insight on Formulation Precautions", AAPS PharmSciTech, 2015, vol. 16, No. 2, p. 407-412.
Downes et al., "A Chemical, Genetic, and Structural Analysis of the Nuclear Bile Acid Receptor FXR," Mol. Cell (2003) 11(4):1079-1092.
FDA Guidance for Industry Q3A Impurities in New Drug Substances (Jun. 2008), 17 pages.
FDA Guidance for Industry, "Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients" Mar. 1998, p. 1-53.
FDA Guidance, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Federal Register, Dec. 29, 2000, vol. 65, No. 251, p. 83041-83063.
Fiorucci et al., "The Nuclear Receptor SHP Mediates Inhibition of Hepaptic Stellate Cells by FXR and Protects Against Liver Fibrosis," Gastroenterology (2004) 127:1497-1512.
Forman et al., "Identification of a Nuclear Receptor That Is Activated by Farnesol Metabolites," Cell (1995) 81:687-693.
Fujiwara et al. "First-principles and Direct Design Approaches for the Control of Pharmaceutical Crystallization", Journal of Process Control, 2005, vol. 15, p. 493-504.
Fukuch I et al., "5β-Cholane activators of the farnesol X receptor," J. Steroid Biochem. Mol. Biol, (2005) 94(4):311-318.
Harwood L. & Moody C. "Organic Reactions: from Starting Materials to Pure Organic Product", Experimental Organic Chemistry, Principles and Practice, 1989, Chapter 3, p. 67-205.
Haslewood et al., "Specificity and some characteristics of a 7a-hydroxysteroid dehydrogenase from E.coli," Database Accession No. 419015 (1978).
Hofmann "The Continuing Importance of Bile Acids in Liver and Intestinal Disease" 159 Arch. Intern. Med., 1999, p. 2647-2658.
Honorio et al., "Hologram QSAR Studies on Farnesoid X Receptor Activators," Lett. Drug Des. Dis. (2006) 3(4):261-267.
Hu & Liu, "Quality Control in Pharmaceuticals: Residual Solvents Testing and Analysis", Wide Spectra of Quality Control, 2011, Ch. 11, p. 183-210.
ICH Harmonised Tripartite Guideline—Impurities in New Drug Substances Q3A(R2); Oct. 2006, 15 pages.
Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH), BioSpace (Jul. 28, 2010), 4 pages.
Intercept Pharmaceuticals, Inc., Press Release, Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease (Oct. 1, 2009), 1 page.
International Search Report issued for PCT/EP02/01832 dated Jun. 18, 2002.
Iverlund et al. "Carbon Cartridges and Their Use as a Purification Step in Pharmaceutical API Processes", Proceedings of European Congress of Chemical Engineering (ECCE-6) Copenhagen Sep. 16-20, 2007, 13 pages.
Kawabata et al. "Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications", International Journal of Pharmaceutics, 2011, vol. 420, p. 1-10.
Kihira et al., "Synthesis of sulfonate analogs of bile acids," Steroids (1992) 57(4):193-198.
Kim et al. "Bile acid sulfonate and 7-alkylated bile acid analogs: Effect on intestinal absorption of taurocholate and cholesterol 7α-hydroxylase activity in cultured rat hepatocytes", Steroids, 2000, vol. 65, Issue 1, p. 24-28.
Kim et al., "Hypocholesterolemic Effect of Bile Acid Sulfonate Analogs in Hamsters," Biol. Pharm. Bulletin (2001) 24(3):218-220.
Kliewer et al., "Peroxisome Proliferator-Activated Receptors: From Genes to Physiology," Endo J (2001) 56:239-263.
Kottke & Rudnic "Tablet dosage forms", Modern Pharmaceutics, Revised & Expanded 4th Edition, 2002, Chapter 10, p. 287-333.
Krishnaiah "Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs", Journal of Bioequivalence & Bioavailability, 2010, vol. 2, Issue 2, p. 28-36.
Kuroki et al. "7-Methyl bile acids: 7β-methyl-cholic acid inhibits bacterial 7-dehydroxylation of cholic acid and chenodeoxycholic acid in the hamster", Journal of Lipid Research, 1987, vol. 28, p. 856-863.
Li et al. "The Role of Intra- and Extragranular Microcrystalline Cellulose in Tablet Dissolution", Pharmaceutical Development and Technology, 1996, vol. 1, No. 4. p. 343-355.
Lieberman et al. "Preformulation Testing", Pharmaceutical Dosage Forms: Tablets, 1989, vol. 1, Ch. 1, 2d ed., p. 1-73.
Liu et al., "Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis," J. Clin. Invest. (2003) 112(11 ): 1678-1687.
Makishima et al. "Identification of a Nuclear Receptor for Bile Acids", Science, 1999, vol. 284, p. 1362-1365.
Mangelsdorf et al., "The RXR Heterodimers and Orphan Receptors," Cell (1995) 83:841-850.
Markarian "Using Micronization to Reduce API Particle Size", PharmaTech.com, Jan. 16, 2013, 3 pages.
Mason et al. "Farnesoid-X Receptor Agonists: A New Class of Drugs For the Treatment of PBC? An International Study Evaluating the Addition of INT-747 to Ursodeoxycholic Acid", Journal of Hepatology, 2010, vol. 52, p. S1-S2.
Mikami et al., "Effect of some sulfonate analogues of ursodeoxycholic acid on biliary lipid secretion in the rat," J. Lipid Res, (1996) 37(6):1181-1188.
Miki et al., "Sulfonate analogues of chenodeoxycholic acid: metabolism of sodium 3α,7α-dihydroxy-25-homo-5β-cholane-25-sulfonate and sodium 3α,7α-dihydroxy-24-nor-5β-cholane-23-sulfonate in the hamster," J. Lipid Res. ( 1992) 33( 11): 1629-1637.
Ml et al., "Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR," Molecular Cell. (2003) 11:1093-1100.
Natalini et al. "Correlation between CMC and chromatographic index: simple and effective evaluation of the hydrophobic/hydrophilic balance of bile acids", Anal. Bioanal. Chem., 2007, vol. 388, p. 1681-1688.
Nesto et al., "Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure," Diabetes Care (2004) 27( 1 ):256-263.
Ng et al. "Suitability of [11,12-3H2]chenodeoxycholic Acid and [11,12-3H2]lithocholic Acid For Isotope Dilution Studies of Bile Acid Metabolism In Man", 1977, Journal of Lipid Research, vol. 18, p. 753-758.
Pavia et al., "Technique 5—Crystallization: Purification of Solids", Organic Laboratory Techniques, 1st Ed., 1998, p. 648-665.
Pellicciari et al. "Farnesoid X Receptor: From Structure to Potential Clinical Applications", Journal of Medicinal Chemistry (2005), 48 (17), p. 1-21.
Pellicciari et al., "6 alpha-ethyl-chenodeoxycholic Acid (6-EDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity," J. Med. Chem. (2002) 45(17):3569-3572.
Pellicciari et al., "Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid," J. Med. Chem. (2004) 47:4559-4569.
Pellicciari et al., "Nongenomic Actions of Bile Acids. Synthesis and Preliminary Characterization of 23- and 6,23-Alkyl-Substituted Bile Acid Derivatives as Selective Modulators for the G-Protein Coupled Receptor TGR5," J. Med. Chem. (2007) 50:4265-4268.
Porez et al., "Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease", Journal of Lipid Research, 2012, vol. 53, p. 1723-1737.
Rajevic et al. "Assay of Ursodeoxycholic Acid and Related Impurities in Pharmaceutical Preparations by HPLC With Evaporative Light Scattering Detector", J. Liq. Chrom. & Rel. Technol., 1998, vol. 21, No. 18, p. 2821-2830.
Raskin et al., "A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes," Diabetes Care (2001) 24(7):1226-1232.
Roda et al. " Structure-activity relationship studies of new 6α-methyl and 6α-fluoro-ursodeoxycholic acid derivatives", Falk Symposium, Bile Acids in Gastroenterology, Basic and Clinical Advances, 1995, vol. 80, p. 27-37.
Roda et al. "HPLC study of the impurities present in different ursodeoxycholic acid preparations: comparative evaluation of four detectors", Journal of Pharmaceutical & Biomedical Analysis, 1993, vol. 11, No. 8, p. 751-760.
Roda et al. "Metabolism, Pharmacokinetics, and Activity of a New 6-Fluoro Analogue of Ursodeoxycholic Acid in Rats and Hamsters", Gastroenterology (1995) 108, 1204-1214 (Year: 1995). *
Roda et al. "New 6-substituted bile acids: physico-chemical and biological properties of 6α-methyl ursodeoxycholic acid and 6α-methyl-7-epicholic acid" Journal of Lipid Research (1994), 35(12), 2268-79.
Roda et al., "23-Methyl-3α,7β-Dihydroxy-5β-cholan-24-oic Acid: Dose-Response Study of Biliary Secretion in Rat," Hepatol. (1988) 8(6):1571-1576.
Roda et al., "Bile Acids with a Cyclopropyl-Containing Side Chain. IV. Physicochemical and Biological Properties of the Four Diastereoisomers of 3α,7β-Dihydroxy-22,23-methylene-5β-cholan-24-oic Acid," J. Lipid Res. (1987) 28(12):1384-1397.
Rohani "Applications of the Crystallization Process in the Pharmaceutical Industry", Front. Chem. Eng. China, 2010, vol. 4, No. 1, p. 2-9.
Rubin et al., "Combination Therapy With Pioglitazone and Insulin in Patients with Type 2 Diabetes," Diabetes (1999) 48 (Suppl. 1):A 110 (Abstract Only).
Russell, DW. "Nuclear Orphan Receptors Minireview Control Cholesterol Catabolism", Cell 97:539-542 (1999).
Sato et al., "Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure-Activity Relationships, and Molecular Modeling Studies," J. Med. Chem. (2008) 51(6):1831-1841.
Savjani et al., "Drug Solubility: Importance and Enhancement Techniques," Internaional Scholarly Research Network, ISRN Pharmaceutics, 2012, vol. 2012, Article ID 195727, 10 pages.
Scalia et al. "Assay of free bile acids in pharmaceutical preparations by HPLC with electrochemical detection", International Journal of Pharmaceutics, 1995, vol. 115, p. 249-253.
Schmider et al., "Evidence for an additional sinusoidal bile salt transport system," Database Accession No. 2000:260886 (2009).
Seol, W. et al., "Isolation of Proteins That Interact Specifically with the Retinoid X Receptor: Two Novel Orphan Receptors", Molecular Endocrinology, 9:72-85 (1995).
Shotton et al. "Effect of Intragranular and Extragranular Disintegrating Agents on Particle Size of Disintegrated Tablets", 1976, Journal of Pharmaceutical Sciences, p. 1170-1174.
Silverman et al. "Drug Discovery, Design, and Development", The Organic Chemistry of Drug Design and Drug Action, First Edition, 1992, Chapter 2, p. 4-51.
Sinal, C. "Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis", Cell 102: 731-744 (2000).
Snyder et al. "Preparative HPLC Separation", Practical HPLC Method Development, Second Edition, 1997, Chapter 13, p. 616-642.
Souillac et al., "Characterization of Delivery Systems, Differential Scanning Calorimetry," Encyclopedia of Controlled Drug Delivery, John Wiley & Sons (1999), pp. 212-227.
Stenner et al., "The Effect of ursodeoxycholic acid on fibrosis markers in alcoholic liver disease," Flak Symposium (2002), pp. 229-235.
Study NCT00550862, A Study of INT 747 (6-ECDCA) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis, Oct. 27, 2007, 7 pages.
Study NCT01265498, The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment (FLINT) Trial, Dec. 21, 2010, 11 pages.
Takahashi et al. "Using Fluid Bed Granulation to Improve the Dissolution of Poorly Water-Soluble Drugs", Brazilian Archives of Biology and Technology, 2012, vol. 55, No. 3, p. 477-484.
Takata et al. "Cocrystal Screening of Stanolone and Mestanolone Using Slurry Crystallization", Crystal Growth & Design, 2008, vol. 8, No. 8, p. 3032-3037.
U.S. Appl. No. 16/832,256, filed Mar. 27, 2020, Pellicciari.
Une et al. "Synthesis of bile acid analogs: 7-alkylated chenodeoxycholic acids", Steroids, 1989, vol. 53/1-2, p. 97-105.
Urizar et al., "A Natural Product that Lowers Cholesterol as an Antagonist Ligand for FXR," Science (2002) 296(5573): 1703-1706.
Vippagunta et al., "Crystalline Solids," Advanced Drug Delivery Reviews (2001) 48:3-26.
Vranic "Amorphous Pharmaceutical Solids", Bosnian Journal of Basic Medical Sciences, 2004, vol. 4, No. 3, p. 35-39.
Wang et al. "Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR", Molecular Cell, 1999, vol. 3, p. 543-553.
Willson et al., "The PPARs: From Orphan Receptors to Drug Discovery," J. Med. Chem. (2000) 43(4):527-550.
Yang et al. "Physical Factors Contributing to Hydrophobic Constant π", Quant. Struct. Act. Relat., 1986, vol. 5, p. 12-18.
Yu "Amorphous pharmaceutical solids: preparation, characterization and stabilization," Advanced Drug Delivery Reviews, 2001, vol. 48, p. 27-42.
Yu et al., "An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR)," Steroids, 2012, vol. 77, p. 1335-1338.

Also Published As

Publication number Publication date
DE60205891T2 (de) 2006-06-22
US7786102B2 (en) 2010-08-31
NO2017022I1 (no) 2017-05-26
ES2248581T3 (es) 2006-03-16
IL157816A (en) 2009-05-04
CA2440680C (en) 2010-06-01
EP1392714B1 (en) 2005-08-31
AU2002308295B2 (en) 2007-08-23
IL157816A0 (en) 2004-03-28
US9732117B2 (en) 2017-08-15
FR17C0003I1 (fr) 2017-07-21
CY2017020I1 (el) 2017-11-14
US20100022498A1 (en) 2010-01-28
CY2017020I2 (el) 2017-11-14
NL300877I2 (nl) 2017-06-22
BE2017C018I2 (enrdf_load_stackoverflow) 2021-02-04
US8058267B2 (en) 2011-11-15
US20120053163A1 (en) 2012-03-01
US8969330B2 (en) 2015-03-03
US20190300564A9 (en) 2019-10-03
US20170305961A1 (en) 2017-10-26
US20150166598A1 (en) 2015-06-18
ATE303399T1 (de) 2005-09-15
US20160152657A1 (en) 2016-06-02
CA2440680A1 (en) 2002-09-19
FR17C0003I2 (fr) 2018-05-25
NO20034011D0 (no) 2003-09-11
US10421772B2 (en) 2019-09-24
EP1392714A1 (en) 2004-03-03
US20140024631A1 (en) 2014-01-23
US8377916B2 (en) 2013-02-19
DE60205891D1 (de) 2005-10-06
NO2017022I2 (no) 2018-08-20
NO326134B1 (no) 2008-10-06
WO2002072598A1 (en) 2002-09-19
US20050080064A1 (en) 2005-04-14
DK1392714T3 (da) 2006-01-09
US20070142340A1 (en) 2007-06-21
US7138390B2 (en) 2006-11-21
JP2007269815A (ja) 2007-10-18
JP2004519492A (ja) 2004-07-02
NO20034011L (no) 2003-11-12
JP4021327B2 (ja) 2007-12-12

Similar Documents

Publication Publication Date Title
US10421772B2 (en) Steroids as agonists for FXR
US7812011B2 (en) Steroid agonist for FXR
AU2002308295A1 (en) Steroids as agonists for FXR
US7858608B2 (en) Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
EP2040713B1 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2004007521A2 (en) Bile acid derivatives as agonists of the farnesoid x receptor

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: INTERCEPT PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PELLICCIARI, ROBERTO;REEL/FRAME:053657/0803

Effective date: 20100317

Owner name: INTERCEPT PHARMACEUTICALS, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PELLICCIARI, ROBERTO;REEL/FRAME:053657/0711

Effective date: 20040527

AS Assignment

Owner name: U.S. BANK NATIONAL ASSOCIATION, CONNECTICUT

Free format text: SECURITY INTEREST;ASSIGNOR:INTERCEPT PHARMACEUTICALS, INC.;REEL/FRAME:057650/0772

Effective date: 20210817

DC Disclaimer filed

Free format text: DISCLAIM THE TERM OF THIS PATENT WHICH WOULD EXTEND BEYOND THE EXPIRATION DATE OF PAT. NOS. 7,786,102; 8,058,267; 8,377,916; 9,732,117 AND 10,421,772

Effective date: 20220207

AS Assignment

Owner name: INTERCEPT PHARMACEUTICALS, INC., NEW JERSEY

Free format text: CHANGE OF ADDRESS;ASSIGNOR:INTERCEPT PHARMACEUTICALS, INC.;REEL/FRAME:060814/0702

Effective date: 20220722

AS Assignment

Owner name: INTERCEPT PHARMACEUTICALS, INC., NEW JERSEY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 16488503 PREVIOUSLY RECORDED AT REEL: 060814 FRAME: 0702. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF ADDRESS;ASSIGNOR:INTERCEPT PHARMACEUTICALS, INC.;REEL/FRAME:061207/0079

Effective date: 20220722

AS Assignment

Owner name: INTERCEPT PHARMACEUTICALS, INC., NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION;REEL/FRAME:066662/0210

Effective date: 20240102